基于溶瘤病毒的肝细胞癌免疫疗法
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.
作者信息
Yoo So Young, Badrinath Narayanasamy, Woo Hyun Young, Heo Jeong
机构信息
BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea.
Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea.
出版信息
Mediators Inflamm. 2017;2017:5198798. doi: 10.1155/2017/5198798. Epub 2017 Apr 20.
Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.
肝细胞癌是一种高度难治的癌症，对传统化疗和放疗具有抗性，预后不佳。尽管已经开发了许多抗癌药物用于治疗肝癌，但索拉非尼是唯一有效的治疗药物，但它只能将生存期延长约3个月。最近，溶瘤病毒疗法在治疗肝癌方面显示出有前景的结果，并且通过采用免疫调节分子可以进一步增强其效果。本文综述了治疗肝癌的现状以及基于溶瘤病毒的免疫疗法治疗肝癌的有效策略。
Zotero 插件